Investment Analysts’ Weekly Ratings Changes for Arcellx (ACLX)

Arcellx (NASDAQ: ACLX) recently received a number of ratings updates from brokerages and research firms:

• 3/2/2026 – Arcellx was downgraded by TD Cowen from “strong-buy” to “hold”.
• 2/25/2026 – Arcellx was downgraded by Guggenheim from “buy” to “neutral”. They now have a $115.00 price target on the stock, down from $120.00.
• 2/24/2026 – Arcellx was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $115.00 price target on the stock, up from $100.00.
• 2/24/2026 – Arcellx was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $115.00 price target on the stock, up from $110.00.
• 2/24/2026 – Arcellx had its “market perform” rating reaffirmed by Leerink Partners. They now have a $115.00 price target on the stock.
• 2/23/2026 – Arcellx had its “hold” rating reaffirmed by Stifel Nicolaus. They now have a $115.00 price target on the stock, down from $127.00.
• 2/23/2026 – Arcellx was given a new $115.00 price target by Evercore Inc.
• 2/23/2026 – Arcellx was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $115.00 price target on the stock.
• 2/23/2026 – Arcellx was downgraded by William Blair from “strong-buy” to “hold”.
• 2/23/2026 – Arcellx was given a new $115.00 price target by Canaccord Genuity Group Inc..
• 2/23/2026 – Arcellx had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $115.00 price target on the stock, up from $106.00.
• 2/23/2026 – Arcellx was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $120.00 price target on the stock, down from $134.00.
• 2/23/2026 – Arcellx was downgraded by Leerink Partners from “strong-buy” to “hold”.
• 2/23/2026 – Arcellx was downgraded by Evercore Inc from “strong-buy” to “hold”.
• 2/23/2026 – Arcellx was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $120.00 price target on the stock, down from $134.00.
• 2/23/2026 – Arcellx was downgraded by Canaccord Genuity Group Inc. from “strong-buy” to “hold”.
• 2/23/2026 – Arcellx was downgraded by Robert W. Baird from “outperform” to “hold”. They now have a $115.00 price target on the stock, up from $106.00.
• 2/23/2026 – Arcellx was downgraded by Needham & Company LLC from “buy” to “hold”.
• 2/23/2026 – Arcellx was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $115.00 price target on the stock.
• 2/12/2026 – Arcellx was downgraded by Rothschild & Co Redburn from “buy” to “neutral”. They now have a $82.00 price target on the stock.
• 2/5/2026 – Arcellx had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $105.00 price target on the stock.
• 2/4/2026 – Arcellx had its “buy” rating reaffirmed by HC Wainwright. They now have a $115.00 price target on the stock.
• 1/21/2026 – Arcellx had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/7/2026 – Arcellx is now covered by UBS Group AG. They set a “buy” rating on the stock.
• 1/7/2026 – Arcellx is now covered by UBS Group AG. They set a “buy” rating and a $100.00 price target on the stock.

Insider Activity at Arcellx

In related news, insider Christopher Heery sold 7,437 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. This represents a 20.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the transaction, the insider owned 276,051 shares in the company, valued at $31,447,729.92. The trade was a 24.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 109,366 shares of company stock worth $11,526,708. Corporate insiders own 8.35% of the company’s stock.

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.